DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20160791

Serum alkaline phosphatase and high sensitivity C-reactive protein in type II diabetes mellitus: a risk of cardio vascular disease in South Indian population

G. Deepika, N. Veeraiah, Syed Naveed, M. V. Ramana

Abstract


Background: Diabetes mellitus (DM) is a clinical syndrome characterized by abnormal metabolism of carbohydrate, protein and fat resulting in hyperglycemia due to absolute or relative deficiency of insulin ending up in vascular complications leading to retinopathy, neuropathy and nephropathy. The aim of the study was to examine the relationship between alkaline phosphatase (ALP) and high sensitive C reactive protein (hsCRP), in type 2 diabetic patients. We assessed the association of ALP and hsCRP levels with CVD complication and determined its utility for CVD risk prediction in type 2 DM subjects with good and poor glycemic control. Further, we investigated correlation between serum ALP and hsCRP level with glycemic control (FBS, PP2BS, HbA1c) in subjects.

Methods: A cross sectional study consists of 390 patients out of which 100 normal healthy control (Group I) , 120 patients having type 2 DM with good control (Group II), 170 patients with type 2 DM with poor control (Group III) were selected. Serum ALP, serum hsCRP, FBS, PP2BS, HbA1c, and other biochemical investigations including serum liver enzymes and lipid profile were measured.

Results: In Study I Mean serum ALP(145.17±23.91) and hsCRP (2.53±0.76) concentration in group II patients when compared to group I serum ALP(142.17±16.48) and Hscrp (1.51±0.15) shows a significance of ALP (p<0.05) and Hscrp (p<0.001).Study II Mean serum ALP(145.17±23.91) and hsCRP (2.53±0.76) concentration in group II patients when compared to group III serum ALP (147.79±28.95) and Hscrp (3.848±0.47) group shows a significance of ALP (p<0.001) and Hscrp (p<0.05). Study III Mean serum ALP (147.79±28.95) and hsCRP (3.848± 0.47) concentration in group III patients when compared to group I serum ALP (142.17±16.48) and Hscrp (1.51±0.15) shows a high significance of both ALP and Hscrp (p<0.001). Further significant positive correlation was observed between ALP and hsCRP concentration as well as with HbA1c, FBS, and PP2BS.

Conclusions: Inflammation along with the poor glycemic control in diabetes play a role in diabetic macrovascular complication like CVD. All these finding are showing a link between CVD, inflammation and glycemic control in patient with type 2 diabetes mellitus.


Keywords


Inflammation, Poor glycemic control, Diabetes, CVD

Full Text:

PDF

References


Thakur S, Chauhan V, Negi RC: Role of HbA1C in diabetes mellitus. J Indian Acad Clin Med. 2009;10(1,2):52-54.

Alvin C: Powers: diabetes mellitus. In Harrison’s Principle of Internal Medicine. 16th edition. Edited by Kasper L, et al. New York: McGraw-Hill. 2005:2152-2179.

Ford ES: The metabolic syndrome and C-reactive protein, fibrinogen and leucocyte count: findings from the third national health and nutrition examination survey. Atherosclerosis. 2003;168:351-8.

Schoppet M, Shanahan CM. Role for alkaline phosphatase as an inducer of vascular calcification in renal failure? Kidney Int. 2008;73(9):989-91.

Moss DW. Release of membrane bound enzymes from cells and the generation of isoforms. Clin Chem Acta. 1994;226:131-42.

Loe H. The sixth complication of diabetes mellitus. J Diabetes Care. 1993;16:476-80.

Enlow DH. Physiologic tooth movement and alveolar remolding. In Enlow DH, ed. Facial Growth. Philadelphia; Saunders. 1999;130-48.

Biasi D, Carletto A, Dell Angola C. Neutrophil migration, oxidative metabolism adhesion in elderly and young subjects. Inflammation. 1999;20:673.

Aiinamo J, Lahtinen A, Uitto V. Rapid periodontal destruction in adult human with poorly controlled diabetes.J Clin Periodontal. 1990;17:22-5.

Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG. Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132-40.

Webber M, Krishnan A, Thomas NG, Cheung BMY. Association between serum alkaline phosphatase and C-reactive protein in the United States National Health and Nutrition Examination Survey 2005–2006. Clin Chem Lab Med. 2010;48(2):167-73.

Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolicsyndrome. Arteriosclerosis, thrombosis, and vascular biology. 2005;25(1):193-7.

Amanullah S, Jarari A, Govindan M: Mohamed Ismail Basha and Saira khatheeja: association of hsCRP with diabetic and non-diabetic individuals.Jordan J Biol Sci. 2010;3(1):7-12.

Steven M: Haffner: the metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiology. 2006;97:3A-11A.

Alvin C: Powers: diabetes mellitus. In Harrison’s Principle of Internal Medicine. 16th edition. Edited by Kasper L, et al. New York: McGraw-Hill. 2005:2152-79.

Kunutsor SK, Apekey TA, Khan H. Liver enzymes and risk of cardiovascular disease in the general population: A meta-analysis of prospective cohort studies. Atherosclerosis. 2014;236(1):7-17.

Biasi D, Carletto A, Dell Angola C. Neutrophil migration, oxidative metabolism adhesion in elderly and young subjects. Inflammation. 1999;20:673.

Aiinamo J, Lahtinen A, Uitto V. Rapid periodontal destruction in adult human with poorly controlled diabetes.J Clin Periodontal. 1990;17:22-8.

Marchesini G, Brizi M, Bianchi G: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844-50.

Chitturi S, Abeygunasekera S, Farrell GC: NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373-9.

Karp DR, Shimooku K, Lipsky PE: Expression of gamma-glutamyl transpeptidase protects ramos B cells from oxidation-induced cell death. J Biol Chem. 2001;276:3798-804.

Schoppet M, Shanahan CM. Role for alkaline phosphatase as an inducer of vascular calcification in renal failure? Kidney Int. 2008;73(9):989-91.

Tonelli M, Curhan G, Pfeffer M, Sacks F, Thadhani R, Melamed ML. Relation Between AlkalinePhosphatase, Serum Phosphate, and All-Cause or Cardiovascular Mortality. Circulation. 2009;120(18):1784-92.

Wannamethee SG, Sattar N, Papcosta O, Lennon L, Whincup PH. Alkaline Phosphatase, Serum Phosphate, and Incident Cardiovascular Disease and Total Mortality in Older Men. Arteriosclerosis, thrombosis, and vascular biology. 2013;33(5):1070-6.

Dilshad Ahmed K, Shazia Q: Evaluation of cardiac risk by oxidative stress and inflammatory markers in diabetic patients. Pak J Med Sci. 2009;25:5.

Sarinnapakorn V, Wanicagool W: Association between hs-CRP and Hba1c in overweight type 2 diabetic female patients. J Med Assoc Thai. 2013;96(3):S54-8.

Bahceci M, Tuzcu A, Ogun C, Canoruc N, Iltimur K, Aslan C: Is serum C-reactive protein concentration correlated with HbA1c and insulin resistance in Type 2 diabetic men with or without coronary heart disease. J Endocrinol Invest. 2005;28(2):145-150.

Malnick SD, Beergabel M, Knobler H: Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. QJM. 2003;96:699-709.

Hanley AJ, Williams K, Festa A: Liver markers and development of the metabolic syndrome. The insulin resistance atherosclerosis study. Diabetes. 2005;54:3140-7.

Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R: Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448-54.

Lee DH, Jacobs DR, Gross M, Kiefe CI, Roseman J, Lewis CE, et al: Gammaglutamyl transferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Clin Chem. 2003;49:1358-66.

Nannipieri M, Gonzales C, Baldi S: Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study.Diabetes Care. 2005;28:1757-62.

Targher G, Bertolini L, Poli F: Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005;54:3541-6.

Hotamisligil GS: Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord. 2003;27(3):S53-5.

Hsueh WA, Quinones MJ: Role of endothelial dysfunction in insulin resistance. Am J Cardiol. 2003;92:10J-17J.